Latest News HighLights
Lirilumab by Bristol-Myers Squibb for Relapsed Multiple Myeloma: Likelihood of Approval
Lirilumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Relapsed Multiple Myeloma. According to GlobalData, Phase II drugs for Relapsed Multiple Myeloma have a 37% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. Smarter leaders trust GlobalData The gold standard of business intelligence. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Lirilumab overview Lirilumab (IPH-2102, BMS-986015) is under development for the treatment of hematologic tumors including refractory or relapsed multiple m The drug candidate is administered intravenously. It targets killer cell immunoglobulin-like receptor 2DL 1, 2 and 3. It was also under development for castrate resistant prostate cancer, colorectal cancer, metastatic melanoma, advanced solid tumors including non-small cell lung cancer, gastrointestinal tract cancer, head and neck cancer, squamous cell carcinoma, hepatocellular carcinoma, myelodysplastic syndrome, Hodgkin lymphoma, non-Hodgkin lymphoma and acute myeloid leukemia (AML). Bristol-Myers Squibb overview Bristol-Myers Squibb (BMS) is a specialty biopharmaceutical company that is engaged in discovery, development, licensing and manufacturing, marketing, distribution and sale of medicines and related medical products to patients with serious diseases. Its primary focus is on cancer, cardiovascular, immunology and fibrotic therapeutic projects. The company offers its products across the world to wholesalers, retail pharmacies, medical professionals, hospitals and government entities. BMS provides its products in the US, Europe, and Japan. The company conducts research to focus on the discovery and development of novel medicines that address serious diseases in areas of significant unmet medical need. BMS is headquartered in New York City, New York, the US. For a complete picture of Lirilumab’s drug-specific PTSR and LoA scores, This content was updated on 11 March 2023 Give your business an edge with our leading industry insights. From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s . Smarter leaders trust GlobalData The gold standard of business intelligence.
Publish Date : 2023-11-19 01:18:47
Image and News Source : pharmaceutical_technology
